Patient Opportunity Trust

Celebrating 20 Years Focused on High Returns

Patient Opportunity Trust

WE SEEK LONG-TERM
GROWTH OF CAPITAL.

A flexible, value fund with a contrarian bent for investors thinking about the long term. Our experienced team has focused on maximizing returns through market cycles for 20 years. With high active share, the Fund offers diversification from the S&P 500. Our approach, implemented by Samantha McLemore, CFA, aims to achieve long term outperformance.

Strategy Highlights

  • We believe that to generate excess returns consistently, we must find market mispricings and capitalize on those gaps between price and intrinsic value. These anomalies are driven most often by the behavioral tendencies of large groups of people. As such, we tend to find the best opportunities during periods of uncertainty.
  • We use a rigorous valuation-based research process to try to assess the long-term free cash flow potential of a business by analyzing such things as its long-term economic model, the quality of assets, management, and capital allocation record.
  • We construct a highly-differentiated, concentrated portfolio from the bottom-up with high active share and a long-term focus.
  • In this market, we believe volatility is the price you pay for long-term returns.
  • Portfolio manager: Samantha McLemore, CFA
  • AUM: $1.40B (as of 4/30/2024)
  • Benchmark: S&P 500
Share ClassTickerCusipInception Date
Class ALGOAX00777X65202/03/2009
Class CLMOPX00777X64512/30/1999
Class FILMOFX00777X63702/13/2004
Class ILMNOX00777X61106/26/2000
Class RLMORX00777X62912/28/2006
Class ISMVISX00777X59508/22/2018

Performance

at a glance

Patient Opportunity Trust returns as of 04/30/2024

This chart illustrates the performance of a hypothetical $10,000 investment made in the Funds Class A at inception (02/03/2009). Assumes reinvestment of dividends and capital gains, but does not reflect the effect of any applicable sales charge or redemption fees. This chart does not imply any future performance. Click and drag on line chart to zoom in to a specific time range.

Patient Opportunity Trust returns as of month ending 04/30/2024

3 MOYTD1 YR3 YR5 YR10 YRInception
02/03/2009
w/o sales charges7.20%6.06%36.68%-8.90%7.14%7.80%14.23%
with sales charges1.04%-0.03%28.81%-10.68%5.87%7.16%13.79%
SP 500 TR4.29%6.04%22.66%8.06%13.19%12.41%14.72%

Patient Opportunity Trust returns as of quarter ending 03/31/2024

3 MOYTD1 YR3 YR5 YR10 YRInception
02/03/2009
w/o sales charges12.06%12.06%41.62%%-6.10%9.52%8.07%14.73%
with sales charges5.62%5.62%33.46%%-7.94%8.24%7.43%14.28%
SP 500 TR10.56%10.56%29.88%11.49%15.05%12.96%15.13%

Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Fund performance current to most recent month-end may be lower or higher than the performance quoted. Patient Capital Management has agreed to waive fees and/or reimburse operating expenses through April 30, 2026, so that such annual operating expenses will not exceed 0.88%, subject to recapture as described below. Performance data shown with load reflects the Class A maximum sales charge of 5.75% and Class C maximum deferred sales charge (MDSC) of 1.00%. Performance for the Class A and C shares shown without load does not reflect the deduction of the sales load or MDSC. If reflected, total return would be reduced.

Class A Expense Ratio
Gross: 2.12%
Net: 2.11%

This chart illustrates the performance of a hypothetical $10,000 investment made in the Funds Class C at inception (12/30/1999). Assumes reinvestment of dividends and capital gains, but does not reflect the effect of any applicable sales charge or redemption fees. This chart does not imply any future performance. Click and drag on line chart to zoom in to a specific time range.

Patient Opportunity Trust returns as of month ending 04/30/2024

3 MOYTD1 YR3 YR5 YR10 YRInception
12/30/1999
w/o sales charges6.98%5.79%35.54%-9.61%6.31%6.98%6.14%
with sales charges5.98%4.79%34.54%-9.61%6.31%6.98%6.14%
SP 500 TR4.29%6.04%22.66%8.06%13.19%12.41%7.20%

Patient Opportunity Trust returns as of quarter ending 03/31/2024

3 MOYTD1 YR3 YR5 YR10 YRInception
12/30/1999
w/o sales charges11.85%11.85%40.42%%-6.84%8.69%7.25%6.40%
with sales charges10.85%10.85%39.42%%-6.84%8.69%7.25%6.40%
SP 500 TR10.56%10.56%29.88%11.49%15.05%12.96%7.41%

Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Fund performance current to most recent month-end may be lower or higher than the performance quoted. Patient Capital Management has agreed to waive fees and/or reimburse operating expenses through April 30, 2026, so that such annual operating expenses will not exceed 0.88%, subject to recapture as described below. Performance data shown with load reflects the Class A maximum sales charge of 5.75% and Class C maximum deferred sales charge (MDSC) of 1.00%. Performance for the Class A and C shares shown without load does not reflect the deduction of the sales load or MDSC. If reflected, total return would be reduced.

Class C Expense Ratio
Gross: 2.88%
Net: 2.87%

This chart illustrates the performance of a hypothetical $10,000 investment made in the Funds Class FI at inception (02/13/2004). Assumes reinvestment of dividends and capital gains, but does not reflect the effect of any applicable sales charge or redemption fees. This chart does not imply any future performance. Click and drag on line chart to zoom in to a specific time range.

Patient Opportunity Trust returns as of month ending 04/30/2024

3 MOYTD1 YR3 YR5 YR10 YRInception
02/13/2004
w/o sales charges7.19%6.05%36.59%-8.97%7.06%7.74%6.16%
SP 500 TR4.29%6.04%22.66%8.06%13.19%12.41%9.73%

Patient Opportunity Trust returns as of quarter ending 03/31/2024

3 MOYTD1 YR3 YR5 YR10 YRInception
02/13/2004
w/o sales charges12.08%12.08%41.55%%-6.17%9.45%8.01%6.48%
SP 500 TR10.56%10.56%29.88%11.49%15.05%12.96%10.00%

Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Fund performance current to most recent month-end may be lower or higher than the performance quoted. Patient Capital Management has agreed to waive fees and/or reimburse operating expenses through April 30, 2026, so that such annual operating expenses will not exceed 0.88%, subject to recapture as described below. Performance data shown with load reflects the Class A maximum sales charge of 5.75% and Class C maximum deferred sales charge (MDSC) of 1.00%. Performance for the Class A and C shares shown without load does not reflect the deduction of the sales load or MDSC. If reflected, total return would be reduced.

Class FI Expense Ratio
Gross: 2.17%
Net: 2.16%

This chart illustrates the performance of a hypothetical $10,000 investment made in the Funds Class I at inception (06/26/2000). Assumes reinvestment of dividends and capital gains, but does not reflect the effect of any applicable sales charge or redemption fees. This chart does not imply any future performance. Click and drag on line chart to zoom in to a specific time range.

Patient Opportunity Trust returns as of month ending 04/30/2024

3 MOYTD1 YR3 YR5 YR10 YRInception
06/26/2000
w/o sales charges7.29%6.17%37.03%-8.67%7.41%8.08%7.18%
SP 500 TR4.29%6.04%22.66%8.06%13.19%12.41%7.36%

Patient Opportunity Trust returns as of quarter ending 03/31/2024

3 MOYTD1 YR3 YR5 YR10 YRInception
06/26/2000
w/o sales charges12.14%12.14%41.99%%-5.87%9.80%8.35%7.45%
SP 500 TR10.56%10.56%29.88%11.49%15.05%12.96%7.58%

Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Fund performance current to most recent month-end may be lower or higher than the performance quoted. Patient Capital Management has agreed to waive fees and/or reimburse operating expenses through April 30, 2026, so that such annual operating expenses will not exceed 0.88%, subject to recapture as described below. Performance data shown with load reflects the Class A maximum sales charge of 5.75% and Class C maximum deferred sales charge (MDSC) of 1.00%. Performance for the Class A and C shares shown without load does not reflect the deduction of the sales load or MDSC. If reflected, total return would be reduced.

Class I Expense Ratio
Gross: 1.88%
Net: 1.85%

This chart illustrates the performance of a hypothetical $10,000 investment made in the Funds Class R at inception (12/28/2006). Assumes reinvestment of dividends and capital gains, but does not reflect the effect of any applicable sales charge or redemption fees. This chart does not imply any future performance. Click and drag on line chart to zoom in to a specific time range.

Patient Opportunity Trust returns as of month ending 04/30/2024

3 MOYTD1 YR3 YR5 YR10 YRInception
12/28/2006
w/o sales charges7.14%5.96%36.25%-9.15%6.85%7.48%5.00%
SP 500 TR4.29%6.04%22.66%8.06%13.19%12.41%9.71%

Patient Opportunity Trust returns as of quarter ending 03/31/2024

3 MOYTD1 YR3 YR5 YR10 YRInception
12/28/2006
w/o sales charges11.95%11.95%41.16%%-6.36%9.23%7.74%5.36%
SP 500 TR10.56%10.56%29.88%11.49%15.05%12.96%10.03%

Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Fund performance current to most recent month-end may be lower or higher than the performance quoted. Patient Capital Management has agreed to waive fees and/or reimburse operating expenses through April 30, 2026, so that such annual operating expenses will not exceed 0.88%, subject to recapture as described below. Performance data shown with load reflects the Class A maximum sales charge of 5.75% and Class C maximum deferred sales charge (MDSC) of 1.00%. Performance for the Class A and C shares shown without load does not reflect the deduction of the sales load or MDSC. If reflected, total return would be reduced.

Class R Expense Ratio
Gross: 2.38%
Net: 2.37%

This chart illustrates the performance of a hypothetical $10,000 investment made in the Funds Class IS at inception (08/22/2018). Assumes reinvestment of dividends and capital gains, but does not reflect the effect of any applicable sales charge or redemption fees. This chart does not imply any future performance. Click and drag on line chart to zoom in to a specific time range.

Patient Opportunity Trust returns as of month ending 04/30/2024

3 MOYTD1 YR3 YR5 YR10 YRInception
08/22/2018
w/o sales charges7.28%6.19%37.09%-8.61%7.48%-4.17%
SP 500 TR4.29%6.04%22.66%8.06%13.19%-12.34%

Patient Opportunity Trust returns as of quarter ending 03/31/2024

3 MOYTD1 YR3 YR5 YR10 YRInception
08/22/2018
w/o sales charges12.18%12.18%42.03%%-5.81%9.89%-5.26%
SP 500 TR10.56%10.56%29.88%11.49%15.05%-13.38%

Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Fund performance current to most recent month-end may be lower or higher than the performance quoted. Patient Capital Management has agreed to waive fees and/or reimburse operating expenses through April 30, 2026, so that such annual operating expenses will not exceed 0.88%, subject to recapture as described below. Performance data shown with load reflects the Class A maximum sales charge of 5.75% and Class C maximum deferred sales charge (MDSC) of 1.00%. Performance for the Class A and C shares shown without load does not reflect the deduction of the sales load or MDSC. If reflected, total return would be reduced.

Class IS Expense Ratio
Gross: 1.78%
Net: 1.77%

Top Ten Holdings
as of 4/30/2024

Amazon.com, Inc.6.37%
Citigroup, Inc.5.69%
Alphabet, Inc. 5.52%
OneMain Holdings, Inc.4.83%
Expedia Group, Inc. 4.80%
Energy Transfer LP 4.71%
Delta Air Lines, Inc.4.47%
General Motors Co.4.45%
Meta Platforms, Inc.3.99%
IAC, Inc. 3.73%

Sector Allocation
as of 4/30/2024

Consumer Discretionary31.36%
Financials23.73%
Communication Services14.53%
Health Care13.41%
Energy10.94%
Industrials8.45%
Information Technology3.08%
Limited Partnership0.11%
Cash-5.61%

Characteristics
as of 4/30/2024

Estimated 1 Year EPS Growth13.57%
Weighted Average Market Cap (billion)$358.85
Price / Earnings11.53
Price Sales Ratio1.08
Price/Book Ratio1.76
Active Share91.42%
Successful investing involves the disciplined and patient execution of a long-term strategy, especially when it is emotionally difficult. That is usually the time the opportunities are the greatest.

– Bill Miller, CFA

Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus or summary prospectus with this and other information about the Fund, please call 800-655-0324. Read the prospectus or summary prospectus carefully before investing.

Mutual fund investing involves risk. Principal loss is possible. An issuer may perform poorly, and therefore, the value of its securities may decline, which would negatively affect the Fund. Derivatives involve special risks including correlation, counterparty, liquidity, operational, accounting and tax risks. These risks, in certain cases, may be greater than the risks presented by more traditional investments. The fund may also use options, which have the risks of unlimited losses of the underlying holdings due to unanticipated market movements and failure to correctly predict the direction of securities prices, interest rates and currency exchange rates. The investment in options is not suitable for all investors. The fund may use leverage which may exaggerate the effect of any increase or decrease in the value of portfolio securities or the Net Asset Value of the fund, and money borrowed will be subject to interest costs. Investments in debt securities typically decrease in value when interest rates rise. The Fund is non-diversified, meaning it may concentrate its assets in fewer individual holdings than a diversified fund. Therefore, the Fund is more exposed to individual stock volatility than a diversified fund. This risk is usually greater for longer-term debt securities. Growth or value securities as a group may be out of favor and underperform the overall equity market while the market concentrates on other types of securities. The Fund may invest in Illiquid securities which involve the risk that the securities will not be able to be sold at the time or prices desired by the fund, particularly during times of market turmoil. The Fund invests in foreign securities which involve greater volatility and political, economic and currency risks and differences in accounting methods. These risks are greater in emerging markets. Small- and Medium-capitalization companies tend to have limited liquidity and greater price volatility than large-capitalization companies. Investing in commodities may subject the Fund to greater risks and volatility as commodity prices may be influenced by a variety of factors including unfavorable weather, environmental factors, and changes in government regulations. Investments in Real Estate Investment Trusts (REITs) involve additional risks such as declines in the value of real estate and increased susceptibility to adverse economic or regulatory developments. The fund may make short sales of securities, which involves the risk that losses may exceed the original amount invested. Investing in ETFs are subject to additional risks that do not apply to conventional mutual funds, including the risks that the market price of the shares may trade at a discount to its net asset value (“NAV”), an active secondary trading market may not develop or be maintained, or trading may be halted by the exchange in which they trade, which may impact a Funds ability to sell its shares.

Diversification does not assure a profit nor protect against a loss in a declining market.

Fund holdings and/or sector allocations are subject to change at any time and are not recommendations to buy or sell any security.

The S&P 500 index is a capitalization weighted index of 500 large capitalization stocks which is designed to measure broad domestic securities markets. Market Cap is the market price of an entire company, calculated by multiplying the number of shares outstanding by the price per share. S&P 500 TR is the Standard & Poor’s index calculated on a total return basis. The total return calculation provides investors with a price plus gross cash dividend return. Gross cash dividends are applied on the ex date of the dividend. Investors cannot invest directly in an index and unmanaged index returns do not reflect any fees, expenses or sales charges. Turnover Ratio is a measure of the fund’s trading activity that is computed by taking the lesser of purchases or sales (excluding all securities with maturities of less than one year) and dividing by average monthly assets. Price-to-earnings Ratio (P/E Ratio) is the weighted average of the price/earnings ratios of the equities held by the Fund. P/E ratio is a company’s current stock price divided by its estimated next 12-months’ earnings per share. Price-to-book ratio (P/B ratio) is a financial ratio used to compare a company’s current market price to its book value. Price-to-sales ratio (P/S ratio) is a valuation metric for stocks. It is calculated by dividing the company’s market cap by the revenue in the most recent year; or, equivalently, divide the per-share stock price by the per-share revenue. Active Share is a measure of the percentage of stock holdings in a manager(s) portfolio that differ from the benchmark index. EPS growth (earnings per share growth) illustrates the growth of earnings per share over time. EPS growth rates help investors identify stocks that are increasing or decreasing in profitability. Free cash flow is earnings before depreciation, amortization, and non-cash charges minus maintenance capital expenditures.

The Patient Opportunity Trust is distributed by Quasar Distributors, LLC.